Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Total 13F shares
-
35,388,332
-
Share change
-
+3,856,700
-
Total reported value
-
$1,499,800,148
-
Put/Call ratio
-
73%
-
Price per share
-
$42.41
-
Number of holders
-
239
-
Value change
-
+$147,459,813
-
Number of buys
-
133
-
Number of sells
-
93
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q1 2020
As of 31 Mar 2020,
CRISPR Therapeutics AG - Common Stock (CRSP) was held by
239 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
35,388,332 shares.
The largest 10 holders included
ARK Investment Management LLC, Versant Venture Management, LLC, Nikko Asset Management Americas, Inc., NEA Management Company, LLC, FEDERATED HERMES, INC., WADDELL & REED FINANCIAL INC, PRICE T ROWE ASSOCIATES INC /MD/, FMR LLC, CREDIT SUISSE AG/, and MORGAN STANLEY.
This page lists
242
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.